We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $120
Praxis Precision Med Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Promising Pipeline and Strategic Developments Position Praxis Precision Medicines for Market Expansion
Jefferies Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $305
Express News | Praxis Precision Medicines Inc : Jefferies Raises Target Price to $305 From $144
GeneDx Announces Biogen, Praxis Precision Medicines And Stoke Therapeutics As The Founding Partners To Its Patient Access Program For Pediatric Epilepsy, Which Provides Access To Whole Exome Sequencing.
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients With New Partners
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
Praxis Precision Medicines to Showcase Updates From Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
Praxis Solutions Welcomes Andre Hatibi as Senior Vice President of Business Development
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $270
Piper Sandler Gives a Buy Rating to Praxis Precision Medicines (PRAX)
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $114 to $120
Praxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Praxis Precision Medicines: Strong Buy Rating Amid Potential Upside and Robust Pipeline Despite Operational Challenges
Express News | HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $120 Price Target
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $114 to $170
Praxis Precision Med Price Target Maintained With a $151.00/Share by Needham
Praxis Precision Medicine Analyst Ratings